Dermatitis, atopic, 5

disease
On this page

Also known as ATOD5atopic dermatitis type 5dermatitis, atopic, susceptibility to, 5

Summary

Dermatitis, atopic, 5 (MONDO:0011608) is a disease. A subtype of dermatitis, atopic, susceptibility to — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

FieldValue
Canonical namedermatitis, atopic, 5
Mondo IDMONDO:0011608
MeSHC565280
OMIM605844
DOIDDOID:0110101
UMLSC1853900
MedGen381292
Is cancer (heuristic)no

Also known as: ATOD5 · atopic dermatitis type 5 · dermatitis, atopic, susceptibility to, 5

Disease family

This is a subtype of dermatitis, atopic, susceptibility to. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease susceptibility › inherited disease susceptibilitydermatitis, atopic, susceptibility todermatitis, atopic, 5

Related subtypes (8): dermatitis, atopic, 2, dermatitis, atopic, 3, dermatitis, atopic, 4, dermatitis, atopic, 6, dermatitis, atopic, 7, dermatitis, atopic, 8, dermatitis, atopic, 9, dermatitis, atopic, 1

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.

No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.